# Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma

> **NCT00317044** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 961 (actual)

## Conditions studied

- Asthma
- GERD

## Interventions

- **DRUG:** Esomeprazole
- **DRUG:** Esomeprazole
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00317044
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 961 (ACTUAL)
- **Last updated:** 2014-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00317044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00317044, "Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00317044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*